tradingkey.logo
tradingkey.logo
Search

TherapeuticsMD Inc

TXMD
Add to Watchlist
2.000USD
+0.010+0.50%
Close 05/15, 16:00ETQuotes delayed by 15 min
23.15MMarket Cap
LossP/E TTM

TherapeuticsMD Inc

2.000
+0.010+0.50%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+0.50%

5 Days

+1.01%

1 Month

-3.85%

6 Months

+2.04%

Year to Date

+22.70%

1 Year

+33.33%

TradingKey Stock Score of TherapeuticsMD Inc

Currency: USD Updated: 2026-05-15

Key Insights

TherapeuticsMD Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TherapeuticsMD Inc's Score

Industry at a Glance

Industry Ranking
110 / 155
Overall Ranking
373 / 4482
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

TherapeuticsMD Inc Highlights

StrengthsRisks
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 132.10% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.02M.
Undervalued
The company’s latest PE is -40.67, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.82M shares, increasing 9.99% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 96.50K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

TherapeuticsMD Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

TherapeuticsMD Inc Info

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Ticker SymbolTXMD
CompanyTherapeuticsMD Inc
CEOWalker (Marlan D)
Websitehttps://www.therapeuticsmd.com/
KeyAI